Pfizer/BioNTech plans to submit data from a Phase 3 trial to the Food and Drug Administration for expanded emergency use authorization of its COVID-19 vaccine for youths ages 12 to 15 years old.
Earlier this month, GSK and Vir found that their experimental COVID treatment, VIR-7831, reduced the risk of hospitalization and deaths among patients by 85%, based on interim data from a study.
Prilosec delayed-release capsules and its generics had a market value of $104.5 million for the 12-month period ended January 2021, according to IQVIA.